Table 2.
Author | Biofunctionalization molecule | Immobilization method | Model | Effects |
---|---|---|---|---|
Shin et al.84 | VEGF | PDA/Dipping | In vitro | VEGF did not produce significantly more HUVEC adhesion than PDA alone; VEGF did support increased CD31 expression |
Du et al.108 | Hyaluronic acid | Covalently bound | In vitro | Increased HUVEC attachment |
Yin et al.63 | Anti-CD34 | 3,4-dihydroxyphenyalinine and l-lysine co-polypeptide linking | In vitro | Attachment and growth of ECs and EPCs increased |
Kuwabara et al.79 | CAG peptide | Mixed into PCL solution for electrospinning fibers | Rat | Higher rate of confluent endothelialization of grafts |
De Visscher et al.43 | SDF-1α | Immersed in fibronectin solution, followed by SDF-1α immersion | Sheep | Four times higher fraction of CD34+ cells adhered; all grafts patent after 3 months |
Williams et al.73 | Laminin type 1 | Covalently bound | Rat | Accelerated neovascularization and endothelialization |
Zheng et al.77 | Nap-FFGRGD | Molecular self-assembly of a hydrogelator75 | Rabbit | Threefold increase in endothelial coverage; 100% patency at 2 and 4 weeks compared to 60% patency in uncoated grafts |
ECs, endothelial cells; EPCs, endothelial progenitor cells; PDA, poly(dopamine), VEGF, vascular endothelial growth factor; HUVEC, human umbilical vein endothelial cells; CAG, cysteine-alanine-glycine; SDF, stromal cell-derived factor; PCL, poly(caprolactone).